Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be ...

A patchwork of internet communities is devoted to the project of ‘awakening’ more digital companions through arcane and enigmatic prompts.

It is certainly possible that today’s bottlenecks will prove to be rather short-lived as companies increasingly learn to ...

And while these personas can be generated through most any chatbot, it seems that OpenAI’s 4o model is the origin point and, ...

I'll walk you through two methods for handling this essential task, plus a third way that achieves total annihilation.

AI in Biotechnology Market worth $22,716.5 million by 2035 with 18.5% CAGR | MarketsandMarkets (TM).

The TRM takes a different approach. Jolicoeur-Martineau was inspired by a technique known as the hierarchical reasoning model ...

New research from UBC Okanagan mathematically demonstrates that the universe cannot be simulated. Using Gödel’s ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Kempf is the chap who keeps VLC going and he blogged earlier this week that the Free Software Foundation Europe (FSFE) gave ...